Essential Partners’s CervoMed CRVO Stock Holding History

Essential Partners’s Portfolio CRVO Stock Details CRVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-7	Closed	-$44	–	2696
2025 Q2	$44	Buy	+7	New	+$60	﹤0.01%	2156

Other funds holding CRVO

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

CFG

Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return

PWM

Perigon Wealth Management San Francisco, California $6.36B AUM 28.76% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

Essential Partners's CRVO Position: Q3 2025 in Review

Essential Partners sold out of CervoMed (CRVO) in Q3 2025, closing a stake of 7 shares — an estimated $44 sold.

Essential Partners first reported a position in CRVO in Q2 2025 and held it in 1 quarter. The position peaked at $44 in Q2 2025. 45 funds tracked by Wall St. Rank hold CRVO as of Q3 2025.

Essential Partners reported no remaining CervoMed position as of Q3 2025 after selling out during the quarter.
Essential Partners sold 7 CervoMed shares in Q3 2025, an estimated $44.
Essential Partners first reported a position in CervoMed in Q2 2025 and held it in 1 quarter.
Essential Partners's CervoMed position peaked at $44 in Q2 2025.
45 funds tracked by Wall St. Rank held CervoMed as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.